Eurofins Discovery Announces Formation of its New Scientific Advisory Board
25 May 2022 | Wednesday | News
Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced the formation of its new Scientific Advisory Board (SAB). Company officials gathered renowned leaders from the pharmaceutical and biotechnology industries to gain strategic insights to address the unmet needs in drug discovery.
Image Source : Public Domain
The SAB is tasked with providing guidance on industry trends, growth opportunities and innovations that will further strengthen Eurofins Discovery's portfolio of products and services for drug discovery and ultimately contribute to improving patients' lives. May 20-23 marked the Eurofins Discovery SAB's inaugural meeting in Boston, Mass.
Founding SAB members represent the breadth of drug discovery expertise from renowned institutions around the globe. Eurofins Discovery welcomes:
- Iris Alroy, Ph.D., Chief Scientific Officer (CSO) of Amina Biotech
- Paul Brennan, Ph.D., CSO of Alzheimer's Research UK Oxford Drug Discovery Institute at University of Oxford, and Professor of Medicinal Chemistry
- John Griffin, Ph.D., an entrepreneur and advisor to science-driven organizations
- Paige Mahaney, Ph.D., Senior Vice President and Corporate Head of Discovery Research at Exelixi
- Kevin Otipoby, Ph.D., Senior Vice President of Immunology at Seismic Therapeutics